Skip to main content

Table 5 Comparison of prevalence, clinical management and outcome of NRF of current study with previous surveys

From: Outcome of neonatal hypoxemic respiratory failure: a livebirth population-based retrospective survey

Year of original data

2004

2007

2008

2012

2010

2015

Network region

Nation-wide multicenter NICU

Hebei province multicenter NICU

Nation-wide multicenter NICU

Northwest multicenter NICU

Huai’an regional all in-hospital

Huai’an regional all in-hospital

NRF

1722

1875

6864

1324

556

788

Prevalence of NRF

13.2a

16.9a

19.7a

13.4a

6.8b

9.9b

Mortality rate

32.1

31.4

24.7

15.4

22.5

18.4

Clinical characteristics

 Male

75.5

72.5

70.9

65.7

71.6

60.4

 GA, weeks (Range)

34.9 ± 4.1 (24–44)

35.0 ± 4.0 (24–43)

34.9 ± 3.9 (23–45)

35.6 ± 3.7 (23–44)

35.3 ± 3.6 (26–43)

34.5 ± 4.0 (25–42)

  < 37 weeks

63.3

63.0

62.5

60.2

64.6

67.0

  < 32 weeks

–

–

23.9

13.1

20.5

28.8

  < 28 weeks

2.6

1.6

2.4

1.0

2.0

4.9

 BW, g (range)

2309 ± 832 (650–6075)

2267 ± 804 (600–5500)

2314 ± 819 (600–6500)

2379 ± 727 (660–4810)

2433 ± 789 (800–4980)

2334 ± 886 (700–5700)

  < 2500 g

59.7

60.9

57.9

59.0

65.3

57.5

  < 1500 g

17.2

17.7

16.6

11.5

11.7

19.8

  < 1000 g

1.9

2.0

2.3

1.0

1.0

2.5

 SNAPPE-II

20 [8, 34]

20 [8, 35]

15 [6, 27]

7 [5, 18]

–

10 [5, 19]

Respiratory therapy

 Surfactant

16.6

28.7

26.8

15.9

14.0

27.8

 CPAP

52.6

69.4

69.2

70.0

67.8

80.8

 MV

61.2

46.7

57.9

32.4

46.9

44.2

 Postnatal steroids

–

15.9

20.5

–

15.6

15.7

Primary diagnosis

 RDS

602 (35.0)

881 (47.0)

3010 (43.9)

488 (36.9)

333 (59.9)

287 (36.4)

  Survival rate

66.2

67.3

76.2

78.6

70.9

78.4

  Surfactant treatment

36.0

58.3

54.8

35.7

21.6

67.9

  Survival rate

   Surfactant

78.8

73.7

79.9

84.2

–

81.5

   Non-surfactant

63.5**

58.6**

71.8**

75.8**

–

70.7

   Differencec

15.3

15.1

8.1

8.4

–

10.8

   Numbers needed to treat

6.5

6.6

12.3

11.9

 

9.3

 RDS with BW < 1500 gd

242 (40.2)

331 (37.6)

816 (27.1)

121 (24.8)

–

118 (41.1)

  Survival rate

54.5

45.3

56.9

55.3

–

59.3

  Surfactant treatment

43.4

43.2

64.2

49.5

–

77.1

  Survival rate

   Surfactant

67.6

54.5

59.8

68.5

–

67.0

   Non-surfactant

44.5**

42.7**

52.2*

53.6**

–

33.3**

   Differencec

13.1

11.8

7.6

14.9

–

33.7

   Numbers needed to treat

7.6

8.5

13.2

6.7

–

3.0

 Pneumonia/sepsis

18.4

25.1

21.7

38.0

27.0

35.3

 Meconium aspiration syndrome

9.5

7.8

7.0

2.2

1.4

1.6

 Congenital anomalies

3.0

–

–

–

0.9

10.2

Complications

 Acquired pneumonia/sepsis

17.1

21.7

14.3

19.2

17.6

21.4

 Neurologic impairment

3.5

2.8

3.9

12.5

1.1

19.9

 Air leak

2.3

1.2

3.1

3.4

5.4

6.0

 Bronchopulmonary dysplasia

1.5

0.4

1.8

1.3

0.2

9.1

 Patent ductus arteriosus

–

1.7

5.1

3.1

–

9.5

 Necrotizing enterocolitis

–

0.6

1.3

2.9

0.2

5.8

 Retinopathy of prematurity

1.0

–

1.2

1.0

–

4.4

 Reference

15

14

17

20

21

Current

  1. All values are presented as mean ± standard deviation (SD), or median [interquartile range, IQR], or n (%) or rate (%) referring to total NRF number in each column unless otherwise indicated
  2. Abbreviations: NRF Neonatal respiratory failure, NICU Neonatal intensive care unit, GA Gestational age, BW Birthweight, SNAPPE-II Score for neonatal acute physiology perinatal extension II, CPAP Continuous positive airway pressure, MV Mechanical ventilation, RDS Respiratory distress syndrome
  3. *P < 0.05, **P < 0.01 vs. survival with surfactant
  4. aReferring to all hospitalized neonates in the multicenter NICUs
  5. bReferring to all hospitalized neonates in the whole region of Huai’an
  6. cThe absolute risk of death rate (difference in percentile) between surfactant and non-surfactant treated sub-groups
  7. dThe percentage in parentheses referring to all RDS in each survey
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us